부산대학교 도서관

Direct oral anticoagulants (DOAC) are becoming more commonly used, and there is an increase in the use of doses other than those indicated for patients’ individual conditions. We have often selected low-dose edoxaban for a number of patients. From 2014 to 2019, we had 528 cases of venous thromboembolism. There were 105 patients with no oral anticoagulants, 249 patients with usual dose of DOAC, 98 patients with low-dose edoxaban, and 78 patients with warfarin. We examined the patient background and hemorrhagic/thrombotic adverse events of the low-dose edoxaban users. In 96 cases of low-dose edoxaban, 40 were proximal type, and 56 were calf type, 11 were symptomatic, and 85 were asymptomatic. The reason for using low-dose was the risk of bleeding in 48 cases and the prevention of thrombus propagation in 48 cases. In 3 of the 48 bleeding risk cases, anticoagulation was discontinued because of bleeding, and hemostasis was achieved promptly, which result in anticoagulation restart. Low-dose edoxaban is useful as an alternative to no anticoagulation or therapeutic dose of anticoagulants, and is an effective treatment option for patients at high risk of bleeding.